Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BURLINGTON, Mass., July 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it has completed the enrollment of TRUST-I, its phase 2 clinical trial with TSO (Trichuris suis ova or CNDO-201) in 250 Crohn’s disease patients.
Help employers find you! Check out all the jobs and post your resume.
